Concepts (124)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endothelial Cells | 6 | 2019 | 1077 | 0.870 |
Why?
|
| Nitric Oxide Synthase Type III | 7 | 2019 | 277 | 0.850 |
Why?
|
| Ritonavir | 3 | 2019 | 71 | 0.810 |
Why?
|
| Ginsenosides | 1 | 2019 | 29 | 0.650 |
Why?
|
| Superoxide Dismutase | 2 | 2019 | 271 | 0.620 |
Why?
|
| Estrogen Receptor beta | 1 | 2019 | 159 | 0.610 |
Why?
|
| Endothelium, Vascular | 5 | 2011 | 906 | 0.510 |
Why?
|
| Vasodilation | 3 | 2011 | 214 | 0.420 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2010 | 65 | 0.350 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 1571 | 0.240 |
Why?
|
| Splanchnic Circulation | 1 | 2024 | 59 | 0.230 |
Why?
|
| Oxidative Stress | 6 | 2019 | 1153 | 0.220 |
Why?
|
| Down-Regulation | 4 | 2019 | 2111 | 0.200 |
Why?
|
| Masoprocol | 2 | 2011 | 17 | 0.190 |
Why?
|
| Burkitt Lymphoma | 1 | 2024 | 344 | 0.190 |
Why?
|
| Venous Thrombosis | 1 | 2024 | 393 | 0.180 |
Why?
|
| Coronary Vessels | 3 | 2010 | 692 | 0.180 |
Why?
|
| Antioxidants | 3 | 2011 | 519 | 0.170 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2019 | 174 | 0.160 |
Why?
|
| Anticoagulants | 1 | 2024 | 837 | 0.150 |
Why?
|
| Transcriptional Activation | 1 | 2019 | 1093 | 0.120 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2015 | 235 | 0.120 |
Why?
|
| Transcription Factor AP-1 | 1 | 2015 | 253 | 0.120 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 998 | 0.120 |
Why?
|
| Swine | 4 | 2011 | 1608 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 395 | 0.110 |
Why?
|
| Health | 1 | 2013 | 55 | 0.110 |
Why?
|
| Hair Follicle | 1 | 2013 | 70 | 0.110 |
Why?
|
| Twist-Related Protein 1 | 1 | 2013 | 133 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2019 | 2473 | 0.100 |
Why?
|
| Larrea | 1 | 2011 | 5 | 0.100 |
Why?
|
| HIV Protease Inhibitors | 1 | 2011 | 73 | 0.100 |
Why?
|
| Benzyl Alcohols | 1 | 2011 | 35 | 0.100 |
Why?
|
| Vasodilator Agents | 2 | 2010 | 233 | 0.100 |
Why?
|
| Cell Line | 1 | 2019 | 5120 | 0.090 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2011 | 139 | 0.090 |
Why?
|
| Resistin | 1 | 2010 | 43 | 0.090 |
Why?
|
| Bradykinin | 1 | 2010 | 83 | 0.090 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 224 | 0.080 |
Why?
|
| Superoxides | 4 | 2011 | 217 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 1571 | 0.080 |
Why?
|
| Ghrelin | 1 | 2008 | 78 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 1576 | 0.080 |
Why?
|
| Vasoconstriction | 1 | 2008 | 109 | 0.080 |
Why?
|
| Homocysteine | 1 | 2008 | 148 | 0.080 |
Why?
|
| CD40 Ligand | 1 | 2008 | 122 | 0.080 |
Why?
|
| Recombinant Proteins | 2 | 2010 | 2930 | 0.070 |
Why?
|
| Pulmonary Artery | 1 | 2011 | 522 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2010 | 258 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2010 | 5019 | 0.070 |
Why?
|
| Cells, Cultured | 3 | 2010 | 5620 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2010 | 6174 | 0.060 |
Why?
|
| RNA Interference | 1 | 2010 | 1409 | 0.060 |
Why?
|
| Aging | 1 | 2013 | 1569 | 0.060 |
Why?
|
| Neoplasms | 2 | 2024 | 15664 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 3368 | 0.050 |
Why?
|
| Animals | 8 | 2015 | 60903 | 0.050 |
Why?
|
| Humans | 11 | 2024 | 269834 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2024 | 747 | 0.040 |
Why?
|
| HIV Infections | 1 | 2011 | 2223 | 0.040 |
Why?
|
| Disease Progression | 2 | 2024 | 6881 | 0.040 |
Why?
|
| Prevalence | 1 | 2024 | 3391 | 0.030 |
Why?
|
| Nitric Oxide | 2 | 2010 | 658 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2015 | 128 | 0.030 |
Why?
|
| Microcirculation | 1 | 2015 | 206 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2015 | 5780 | 0.030 |
Why?
|
| Time Factors | 2 | 2024 | 13246 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 512 | 0.030 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2015 | 228 | 0.030 |
Why?
|
| Incidence | 1 | 2024 | 5874 | 0.030 |
Why?
|
| Texas | 1 | 2024 | 6440 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2015 | 838 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 7690 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2015 | 505 | 0.030 |
Why?
|
| Morphogenesis | 1 | 2013 | 346 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2013 | 701 | 0.020 |
Why?
|
| Cell-Free System | 1 | 2011 | 151 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2011 | 83 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2011 | 169 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2010 | 4881 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2024 | 7106 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 16015 | 0.020 |
Why?
|
| Electromyography | 1 | 2011 | 235 | 0.020 |
Why?
|
| Catalase | 1 | 2010 | 71 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2010 | 133 | 0.020 |
Why?
|
| Mutation | 1 | 2010 | 15577 | 0.020 |
Why?
|
| Mammary Glands, Animal | 1 | 2013 | 546 | 0.020 |
Why?
|
| Glutathione | 1 | 2011 | 369 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2010 | 300 | 0.020 |
Why?
|
| Anions | 1 | 2008 | 40 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2011 | 1631 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2010 | 341 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2008 | 115 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2010 | 481 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 3092 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2010 | 580 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 2008 | 155 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 1221 | 0.020 |
Why?
|
| Tissue Engineering | 1 | 2010 | 270 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2008 | 333 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 3147 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 690 | 0.020 |
Why?
|
| Risk Factors | 1 | 2024 | 18032 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2010 | 400 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 523 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 5237 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 877 | 0.010 |
Why?
|
| Oxygen | 1 | 2008 | 780 | 0.010 |
Why?
|
| Mice | 2 | 2015 | 35260 | 0.010 |
Why?
|
| Female | 3 | 2024 | 146824 | 0.010 |
Why?
|
| Atherosclerosis | 1 | 2010 | 971 | 0.010 |
Why?
|
| DNA Damage | 1 | 2010 | 1978 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 16270 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2024 | 39453 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 14842 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 3248 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 9035 | 0.010 |
Why?
|
| Male | 2 | 2024 | 127192 | 0.010 |
Why?
|
| Aged | 1 | 2024 | 72701 | 0.010 |
Why?
|
| Adult | 1 | 2024 | 80478 | 0.010 |
Why?
|
| Middle Aged | 1 | 2024 | 89237 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 2342 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 4894 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 12095 | 0.010 |
Why?
|